Centrexion Therapeutics Corp. logo

Centrexion Therapeutics Corp.

We aim to relieve the suffering associated with chronic pain by creating treatments that address the safety and efficacy gaps in the current treatment paradigm. Centrexion Therapeutics, Inc., is focused on developing and commercializing new, non-opioid and non-surgical treatments for moderate to severe chronic pain.

Centrexion Therapeutics was founded in Nov 2013 and is led by former Celgene Chairman and CEO, Sol Barer, and Jeffrey Kindler, former Chairman and CEO of Pfizer, who serves as the companys CEO.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://centrexion.com
Founded2013
Disease Focus
Development Stage
STOCK CODENon Listed
Address
200 State Street 6th Floor Boston, MA 02109
Baltimore
United States
Email
Contact Number
+1 617 837 6911

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/centrexion-therapeutics-corp-” connections=”true” suffix=””]

Centrexions STRATI_ technology (Synthetic TRans cApsaicin ulTra-pure Injection) provides rapid onset, high degree and long duration of relief from localized moderate to severe pain. Its uses synthetic form of trans-capsaicin that is injected directly into the site of pain and gives fast-acting, long-lasting and targeted pain relief.

In Mar 2016, Centrexion Therapeutics, acquired three new analgesic candidates CNTX-6970, CNTX-6016 and CNTX-0290 from Boehringer Ingelheim. The financial terms of the acquisition were not disclosed.

Centrexion Therapeutics is well financed and had raised nearly $58Mn till mid of 2016.

In Jan 2018,Centrexion received $67Mn in Series D financing led by New Enterprise Associates (NEA), Quan Capital, ArrowMark Partners, along with 6 Dimensions Capital, and Efung Capital. It will be used for the proceeding of phase III CNTX-4975.